Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences
Open accessThe DOI matches its Crossref record; 153 of the 153 references it cites were found in a registry or an index; 26 of the 102 sources its claims cite were checked for support.
Abstract
The prevalence of sarcopenic obesity is increasing worldwide, particularly amongst aging populations. Insulin resistance is the core mechanism of sarcopenic obesity and is also associated with variable cardiometabolic diseases such as cardiovascular disease, type 2 diabetes mellitus, and non-alcoholic fatty liver disease. Fat accumulation in muscle tissue promotes a proinflammatory cascade and oxidative stress, leading to mitochondrial dysfunction, impaired insulin signaling, and muscle atrophy. To compound the problem, decreased muscle mass aggravates insulin resistance. In addition, the crosstalk between myokines and adipokines leads to negative feedback, which in turn aggravates sarcopenic obesity and insulin resistance. In this review, we focus on the molecular mechanisms linking sarcopenic obesity and insulin resistance with various biological pathways. We also discuss the impact and mechanism of sarcopenic obesity and insulin resistance on cardiometabolic disease.
Overview
CoChat Summary
TL;DR
This narrative review argues that insulin resistance is the core mechanism linking sarcopenic obesity to cardiometabolic disease through fat accumulation, inflammation, mitochondrial dysfunction, and impaired insulin signaling in skeletal muscle. It further discusses how myokine–adipokine crosstalk and hormonal changes aggravate sarcopenic obesity and its cardiovascular, metabolic, and hepatic consequences.
Key findings
- Sarcopenic obesity is associated with a 2–3 times higher risk of functional disability than either sarcopenia or obesity alone, and it combines muscle loss with fat accumulation, including intramyocellular lipid, intermyocellular adipose tissue, and peri-muscular adipose tissue.
- In skeletal muscle, lipid intermediates such as DAG and ceramides activate PKC, JNK, IKK/NF-kB, and related pathways, causing serine/threonine phosphorylation of insulin receptor/IRS-1, impaired PI3K/Akt signaling, and reduced GLUT4 translocation; this impairs glucose uptake and promotes muscle atrophy.
- Inflammation is central: adipose tissue macrophage staining is approximately 10% in lean subjects but up to 50% in obese subjects, and proinflammatory cytokines such as TNF-α, IL-1β, and IL-6 contribute to insulin resistance, muscle atrophy, and cardiometabolic disease.
- Sarcopenic obesity and insulin resistance are linked clinically to atherosclerosis/cardiovascular disease, chronic heart failure, type 2 diabetes mellitus, metabolic syndrome, and NAFLD; skeletal muscle accounts for approximately 80–90% of postprandial glucose uptake, making muscle insulin resistance crucial in diabetes pathogenesis.
Methods
- Design: narrative review of molecular and clinical literature on sarcopenic obesity, insulin resistance, and cardiometabolic disease.
- Data/sample: no primary cohort or experimental sample; the paper synthesizes prior human, animal, and in vitro studies and cites clinical examples, including studies on carotid intima-media thickness, myocardial infarction, chronic heart failure, type 2 diabetes, metabolic syndrome, and NAFLD.
- Main analysis: thematic synthesis of mechanisms, including fat accumulation, inflammation, sex/growth hormone deficiency, skeletal muscle insulin signaling pathways, myocyte–adipocyte crosstalk, and pathophysiological links to cardiometabolic diseases.
Limitations
- The paper states that the definition of sarcopenic obesity has not been universally established and that different diagnostic criteria have different clinical implications.
- The paper repeatedly notes conflicting or insufficient evidence, including controversy over irisin and exercise, adiponectin’s clinical role, JAK/STAT signaling in muscle insulin resistance, and whether obesity itself is more predictive than sarcopenia for metabolic syndrome in some studies.
- Evident from the text: as a narrative review without a stated systematic search strategy, risk-of-bias assessment, or meta-analysis, it cannot quantify effect sizes or resolve heterogeneity across the cited studies.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
20 Valid · 4 Not valid · 62 Not checked · 9 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“A British regional health study reported that older subjects with sarcopenic obesity had the highest cardiovascular mortality [113].”
§ Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences > 4. Pathophysiological Link among Cardiometabolic Disease, Sarcopenic Obesity, and Insulin Resistance > 4.1. Atherosclerosis and Cardiovascular Disease
What the sources say
- Disputedcites [113] Atkins J.L. Whincup P.H. Morris R.W. Lennon L.T. Papacosta O. Wannamethee S.G. Sarcopenic obesity and risk of cardiovascular disease and mortality: A population-based cohort study of older men J. Am. Geriatr. Soc. 2014 62 253 260 10.1111/jgs.12652 24428349 PMC4234002 sourceExperimental — accuracy not yet measured
Our copy (Abstract Conclusion; Discussion, and Discussion > Strengths and Limitations) states the opposite for cardiovascular mortality: 'Sarcopenic obese men had the highest risk of all-cause mortality but not CVD mortality,' and the Abstract Results add that CVD mortality risk was significantly greater in sarcopenic and obese but NOT sarcopenic obese men. The only point at which the sarcopenic obese group topped CVD mortality was the age-adjusted model, which lost significance after adjustment for lifestyle variables (Results). The highest-risk finding the paper reports for sarcopenic obesity is all-cause mortality (HR = 1.72, 95% CI = 1.35–2.18), so the claim substitutes CVD mortality for all-cause mortality; it also generalises 'older men' (British Regional Heart Study, aged 60–79) to 'older subjects'. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This complex disorder results in a 2–3 times higher risk of functional disability than either sarcopenia or obesity alone [14].”
§ Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences > 2. Sarcopenia and Sarcopenic Obesity > 2.1. Definition
What the sources say
- Partly supportedcites [14] Rolland Y. Lauwers-Cances V. Cristini C. Abellan van Kan G. Janssen I. Morley J.E. Vellas B. Difficulties with physical function associated with obesity, sarcopenia, and sarcopenic-obesity in community-dwelling elderly women: The EPIDOS (EPIDemiologie de l’OSteoporose) Study Am. J. Clin. Nutr. 2009 89 1895 1900 10.3945/ajcn.2008.26950 19369381 sourceExperimental — accuracy not yet measured
The Results (page unavailable) report roughly 2–3 times higher odds of difficulty with several physical tasks for sarcopenic-obese women than for purely sarcopenic women. Compared with purely obese women, however, the difference was statistically significant only for going down stairs. The study measured self-reported functional difficulties in a cross-sectional sample, not a general 2–3-fold higher risk of developing disability than either group. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Intermyocellular adipose tissue (IMAT) and IMCL secrete myostatin, CCL2, TNF-α, IL-1β, and IL-6, thus inducing IR and lipotoxicity, which is discussed in the next section [30].”
§ Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences > 2. Sarcopenia and Sarcopenic Obesity > 2.2. Molecular Mechanism of Sarcopenic Obesity
What the sources say
- Partly supportedcites [30] Rivas D.A. McDonald D.J. Rice N.P. Haran P.H. Dolnikowski G.G. Fielding R.A. Diminished anabolic signaling response to insulin induced by intramuscular lipid accumulation is associated with inflammation in aging but not obesity Am. J. Physiol. Regul. Integr. Comp. Physiol. 2016 310 R561 R569 10.1152/ajpregu.00198.2015 26764052 PMC4867383 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) links lipid accumulation in obesity to inflammation and secretion of TNF-α, IL-1β, and IL-6. It does not say that IMAT and IMCL themselves secrete those cytokines or myostatin and CCL2, nor does it establish that such secretion induces insulin resistance and lipotoxicity. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The amount of PMAT is correlated with the severity of muscle atrophy [31].”
§ Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences > 2. Sarcopenia and Sarcopenic Obesity > 2.2. Molecular Mechanism of Sarcopenic Obesity
What the sources say
- Supportedcites [31] Zhu S. Tian Z. Torigoe D. Zhao J. Xie P. Sugizaki T. Sato M. Horiguchi H. Terada K. Kadomatsu T. Aging-and obesity-related peri-muscular adipose tissue accelerates muscle atrophy PLoS ONE 2019 14 e0221366 10.1371/journal.pone.0221366 31442231 PMC6707561 source
The Results section, “PMAT accumulation increases with muscle atrophy in aged mice,” reports that mice with at least 5% PMAT had lower muscle mass and muscle-fiber cross-sectional area than mice with less than 5% PMAT. The authors describe the degree of PMAT deposition as associated with progression of muscle atrophy in aged mice. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Low GH levels reduce IGF1 action by sequentially downregulating the PI3K-AKT/PKB-mTOR pathway, which induces protein synthesis in muscles [49].”
§ Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences > 2. Sarcopenia and Sarcopenic Obesity > 2.2. Molecular Mechanism of Sarcopenic Obesity
What the sources say
- Partly supportedcites [49] Egerman M.A. Glass D.J. Signaling pathways controlling skeletal muscle mass Crit. Rev. Biochem. Mol. Biol. 2014 49 59 68 10.3109/10409238.2013.857291 24237131 PMC3913083 sourceExperimental — accuracy not yet measured
The section on IGF1/PI3K/Akt hypertrophy signaling (page not provided) describes IGF1 activating PI3K/Akt and mTORC1 signaling in skeletal muscle; its Figure 1 caption links that signaling to protein synthesis. The passages do not say that low growth hormone (GH) levels reduce IGF1 action or downregulate this pathway. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
43 more claims · 9 with their cited sources checked
Create a free account to see all 95 claims and to verify the 76 references still open.
- It may state two separate claims as one. 44
- Probably not a substantial claim. 5
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Various myokines released from active muscles act as signalling mediators between skeletal muscle and other vital organs, such as the liver, fat, and brain.[ 5 ]”
From Pathogenesis of sarcopenia and the relationship with fat mass: descriptive review (2022) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Secondly, metabolic disorders including cardiometabolic syndrome (CMS), diabetes, cardiovascular disease (CVD), and cancer are common comorbidities of SO (54, 55).”
From Diabetes and Sarcopenic Obesity: Pathogenesis, Diagnosis, and Treatments (2020) · cites this paper as [54]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Obesity can independently lead to loss of muscle mass and function, due to the negative impact of adipose tissue-dependent metabolic derangements, such as oxidative stress, in fl ammation, and insulin resistance, all which negatively affect muscle mass [6].”
From Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement (2022) · cites this paper as [6]
In the citing paper
“Aging-associated increases in visceral fat and reduced muscle mass are correlated with multiple adverse cardiometabolic effects and contribute to poor health outcomes (119).”
From Health Consequences of Sarcopenic Obesity: A Narrative Review (2020) · cites this paper as [119]
In the citing paper
“Obesity can independently lead to loss of muscle mass and function, due to the negative impact of adipose tissue-dependent metabolic derangements, such as oxidative stress, inflammation and insulin resistance, all of which negatively affect muscle mass [6].”
From Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement (2022) · cites this paper as [6]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818 · cited 3×
“EWGSOP2 [2] Use the SARC-F questionnaire to find subjects with sarcopenia Decreased muscle mass and Decreased muscle strength or performance NA”
BackgroundMethodObesity is associated with macrophage accumulation in adipose tissue
Weisberg, S. P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R. L., & Ferrante, A. W. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200319246 · Cited by 10,041 · cited 1×
“In adipose tissue from lean subjects, approximately 10% of cells stained positive for macrophages, but in obese subjects, this number increased to up to 50% [38].”
BackgroundInflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773 · cited 1×
“Atherogenesis is a complicated process that includes oxidative stress, inflammation, endothelial dysfunction, vascular proliferation, and thrombosis [104].”
BackgroundIncreased oxidative stress in obesity and its impact on metabolic syndrome
Furukawa, S., Fujita, T., Shimabukuro, M., Iwaki, M., Yamada, Y., Nakajima, Y., Nakayama, O., Makishima, M., Matsuda, M., & Shimomura, I. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21625 · Cited by 5,508 · cited 2×
“It causes the dysregulation of adipocytokines, such as adiponectin, PAI-1, IL-6, and MCP-1, leading to metabolic syndrome [134].”
BackgroundA PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis
Boström, P., Wu, J., Jedrychowski, M. P., Korde, A., Ye, L., Lo, J. C., Rasbach, K. A., Boström, E. A., Choi, J. H., Long, J. Z., et al. (2012) · Nature · doi:10.1038/nature10777 · Cited by 4,810 · cited 1×
“Irisin is a PPARγ-coactivator-1α (PGCα)-dependent myokine that stimulates browning in subcutaneous adipose tissues and induces increased energy expenditure, which improves obesity and IR through the MAPK and ERK pathways [92,93].”
BackgroundYamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M., Kita, S., Ueki, K., et al. (2002) · Nature Medicine · doi:10.1038/nm788 · Cited by 4,238 · cited 1×
“Thus, it facilitates insulin sensitivity by increasing glucose uptake in skeletal muscle and by stimulating fatty acid oxidation through activation of the 5′-AMP-activated protein kinase (AMPK) signaling pathway [100].”
BackgroundSarcopenia in Asia: Consensus Report of the Asian Working Group for Sarcopenia
Chen, L.-K., Liu, L.-K., Woo, J., Assantachai, P., Auyeung, T.-W., Bahyah, K. S., Chou, M.-Y., Chen, L.-Y., Hsu, P.-S., Krairit, O., et al. (2014) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.11.025 · Cited by 4,051 · cited 3×
“Sarcopenia results in a decreased metabolic rate, low physical activity, and myokine deficiency, which collectively leads to the proinflammatory effect, and exacerbates obesity.”
BackgroundInfluentialSarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afz046 · Cited by 3,803
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 2×
“Moreover, obesity accompanies the accumulation of lipids in the liver, thus aggravating insulin resistance in hepatocytes [141].”
BackgroundA Novel Paradigm for Heart Failure With Preserved Ejection Fraction
Paulus, W. J., & Tschöpe, C. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.092 · Cited by 3,564 · cited 1×
“Inflammation due to sarcopenic obesity results in reduced NO, cyclic guanosine monophosphate (cGMP), and protein kinase G (PKG) activity in cardiomyocytes, leading to LV hypertrophy and stiffness [120].”
Background
Research works printed but not linked: 1
- White A.T. Schenk S. Knockout of STAT3 in skeletal muscle does not enhance insulin action Diabetologia 2013 56 S250
Cited by
Items 101–200 of 400
Franco‐Obregón, A., Tai, Y. K., Wu, K. Y., Iversen, J. N., & Wong, C. J. K. (2023) · Bioengineering · doi:10.3390/bioengineering10080956 · Cited by 18
Polo-Ferrero, L., Martin, M. J., Puente-González, A. S., Barbero-Iglesias, F. J., González-Manzano, S., & Méndez-Sánchez, R. (2025) · Nutrients · doi:10.3390/nu17111822 · Cited by 21
“In addition, obesity may independently contribute to muscle atrophy through adverse metabolic mechanisms associated with adipose tissue, such as oxidative stress, chronic low-grade inflammation, and insulin resistance, all of which negatively impact skeletal muscles [5].”
Copeland, E. N., LeBlanc, P. J., Duarte‐Guterman, P., Fajardo, V. A., & MacPherson, R. E. K. (2025) · The Journal of Physiology · doi:10.1113/jp288032 · Cited by 18
“…a neurotrophic factor, may provide a link between sarcopenic obesity and AD as it has been shown to be lower in patients with AD (Ng et al., 2019), sarcopenia (Miyazaki et al., 2021) and those living with obesity (Craft et al., 1993; Hong & Choi, 2020; Kinney et al., 2018; Luchsinger et al., 2004).”
Role of plasminogen activator inhibitor-1 (PAI-1) in age-related cardiovascular pathophysiology
Khoddam, A., Vaughan, D. E., & Wilsbacher, L. D. (2025) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2024.38 · Cited by 21
“Muscle atrophy during aging is linked to metabolic disorders due to impaired insulin sensitivity, reduced mitochondrial function, and chronic low-grade inflammation, which collectively disrupt protein synthesis and muscle regeneration [84] .”
Jung, C., & Mok, J. (2022) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes22058 · Cited by 17
Hu, T., Shen, Y., Cao, W., Xu, Y., Wang, Y., Ma, X., & Bao, Y. (2023) · Nutrition & Metabolism · doi:10.1186/s12986-023-00727-2 · Cited by 16
“The activation of oxidative stress [34] and the sympathetic nervous system [35] are also involved in the progression of CVD.”
BackgroundTan, L. F., Chan, Y. H., Anbarasan, D., & Merchant, R. A. (2023) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2023.105289 · Cited by 20
Zhou, S., Luo, N., Si, H., Da, W., Liu, Y., Wu, L., Li, M., & Shen, B. (2024) · Aging Clinical and Experimental Research · doi:10.1007/s40520-024-02847-y · Cited by 15
“Data from 2010 to 2012 revealed that 22.7% of the US population had doctor-diagnosed arthritis, with projections such as inflammation, oxidative stress, and insulin resistance [11, 12].”
BackgroundInfluentialLi, M., Yu, B., Yang, H., He, H., Li, N., Lv, A., Zhou, X., & Gao, R. (2024) · Journal of Health Population and Nutrition · doi:10.1186/s41043-024-00690-5 · Cited by 20
Liu, J., Yu, X., Huang, X., Lai, Q.-Q., & Chen, J. (2023) · Cancer Imaging · doi:10.1186/s40644-022-00514-x · Cited by 17
“There is mounting evidence that cardiometabolic diseases are related to myosteatosis and insulin resistance, and both have important roles in disease development [34].”
BackgroundQiu, Y., Laguna, J. C., Alegret, M., & Vilà, L. (2026) · Nutrients · doi:10.3390/nu18040679 · Cited by 16
“However, in states of IR, adipocytes become resistant to this anti-lipolytic effect, leading to uncontrolled hydrolysis of stored TG and a consequent excessive release of NEFAs into the portal circulation [43].”
Matsuba, I., Fujita, R., & Iida, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065847 · Cited by 17
“In the elderly, lipotoxicity acts synergistically with sarcopenia to cause various chronic diseases, such as cardiovascular diseases [10,11].”
BackgroundYang, K., Liu, C., Shao, J., Guo, L., Wang, Q., Meng, Z., Jin, X. Y., & Chen, X. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s448165 · Cited by 16
“4 Consequently, the accumulation of fatty acids (FAs) and triglycerides (TGs) is further exacerbated.”
BackgroundAndrogens as the “old age stick” in skeletal muscle
Gentile, G., Stefano, F. D., Sorrentino, C., D’Angiolo, R., Lauretta, C., Giovannelli, P., Migliaccio, A., Castoria, G., & Donato, M. D. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02163-6 · Cited by 20
“Sarcopenia, however, rarely occurs alone, as it is often accompanied by other syndromes, such as osteoporosis, insulin-resistance, obesity and metabolic syndrome [148, 149].”
Chucherd, O., Vallibhakara, O., Vallibhakara, S. A.-O., Sophonsritsuk, A., Chattrakulchai, K., & Anantaburarana, M. (2025) · Archives of Osteoporosis · doi:10.1007/s11657-025-01573-w · Cited by 15
“The interaction among fat, muscle, and bone tissue in sarcopenic obesity may contribute to changes in bone density and an increased risk of osteoporosis [14, 15].”
Usefulness of Muscle Ultrasound to Study Sarcopenic Obesity: A Pilot Case-Control Study
Simó-Servat, A., Ibarra, M., Libran, M., Rodríguez, S., Perea, V., Quirós, C., Orois, A., Pérez, N., Simó, R., & Barahona, M. J. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11102886 · Cited by 16
“There is emerging evidence indicating that SO may be associated with an increased risk of global mortality and cardiovascular risk factors compared to sarcopenia or obesity alone [8,9].”
BackgroundAssociations of Dynapenic Obesity and Sarcopenic Obesity with the Risk of Complications in COVID-19
Mayoral, L. P.-C., Matias‐Cervantes, C. A., Pérez‐Campos, E., Díaz, C. R., Barrios, L. Á. L., Pina-Canseco, M. D. S., Cruz, M. M., Mayoral, E. P., Solórzano-Mata, C. J., Canales, F. J. R., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158277 · Cited by 14
“and oxidative stress, as consequence stimulating mitochondrial dysfunction, muscle atrophy and insulin resistance [29].”
BackgroundWei, H., Zhang, J., Cui, K., & Su, H. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1575580 · Cited by 13
“Insulin resistance is the central mechanism underlying SO and is associated with diverse cardiometabolic disorders (18).”
Luo, Y., Shu, L., Wang, Y., Zhao, X., Han, M., Liu, Y., Xu, Y. J., & Han, B. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01909-z · Cited by 15
“Consistent with multiple studies [6, 8, 16, 17, 30], our research showed that the clinical relevance of SO in adverse health outcomes was in fl uenced by the diagnostic criteria.”
Xiang, S., Li, Y., Li, Y., Zhang, J., Pan, W., Lu, Y., & Liu, S. (2023) · The journal of nutrition health & aging · doi:10.1007/s12603-023-1967-0 · Cited by 17
Association of Body Composition and Sarcopenia with NASH in Obese Patients
Schmitz, S. M., Schooren, L., Kroh, A., Koch, A. H., Stier, C. K., Neumann, U. P., Ulmer, T. F., & Alizai, P. H. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10153445 · Cited by 13
“Higher amounts of body fat can be seen as predisposing factors for the development of NAFLD and NASH [12–14].”
BackgroundInfluentialSabarathinam, S., Satheesh, S., & Raja, A. (2023) · Obesity Medicine · doi:10.1016/j.obmed.2023.100497 · Cited by 19
Ard, J. D., Neeland, I. J., Rothberg, A. E., Chilton, R. J., de Luis, D., Cohen, S. S., & Johansen, O. E. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15392 · Cited by 12
“17 There is also a lack of data from longer-term studies (beyond 26 weeks), which is important given challenges with longer-term acceptance of use (i.e. MR product fatigue), assessment of potential weight-rebound and to broaden the understanding of longer-term efficacy on weight and on CV risk…”
BackgroundStudy on the comorbid mechanisms of sarcopenia and late-life depression
Wu, J., Tang, J., Huang, D., Wang, Y., Zhou, E., Ru, Q., Xu, G., Chen, L., & Wu, Y. (2025) · Behavioural Brain Research · doi:10.1016/j.bbr.2025.115538 · Cited by 12
“Elevated IL-6 levels have been shown to activate NF-κ B transcription factors, leading to muscle protein degradation[228], and to inhibit PI3K/Akt signaling, thereby impairing protein synthesis[230].”
LeDrew, M., Sadri, P., Peil, A., & Farahnak, Z. (2025) · Nutrients · doi:10.3390/nu17172758 · Cited by 16
“In addition to mobility, muscles play a key role in metabolic processes, regulating energy metabolism and insulin sensitivity, thus helping prevent conditions such as type 2 diabetes, obesity, and cardiovascular disease [10,11].”
Xu, Z., Wang, Q., Zhang, Z., Zhu, Y., Chen, Y., Tang, D., & Zhao, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1144516 · Cited by 13
“Characteristics Number (%) Age (year) median (range) 67 (41-88)”
BackgroundGlobal burden of type 2 diabetes attributable to non-high body mass index from 1990 to 2019
Wu, J., Feng, Z., Duan, J., Li, Y., Deng, P., Wang, J., Yang, Y., Meng, C., Wang, A., Wang, J., et al. (2023) · BMC Public Health · doi:10.1186/s12889-023-15585-z · Cited by 15
“(1) Insulin resistance plays an integral role in the pathogenesis of T2DM and also is the core mechanism of sarcopenic obesity, related to visceral fat deposition and reduced muscle mass [35, 36].”
BackgroundTherapeutic strategies to modulate gut microbial health: Approaches for sarcopenia management.
Das, S., Preethi, B., Kushwaha, S., & Shrivastava, R. (2024) · PubMed · doi:10.14670/hh-18-730 · Cited by 16
Asociación entre obesidad sarcopénica con resistencia a la insulina y síndrome metabólico
Pérez‐Cruz, E., Castro-Martínez, D., & Guzmán, O. P. G. (2021) · Medicina Clínica · doi:10.1016/j.medcli.2021.07.023 · Cited by 13
Bužga, M., Pekár, M., Uchytil, J., Horká, V., Malůš, J., Vilímek, D., Švagera, Z., Kutáč, P., & Holéczy, P. (2023) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2022.7786 · Cited by 15
“An additional research topic addressed in the present studymight include the description of pathophysiological mechanisms and answering the question of how and whether exercise or physical activity can overcome the “metabolic adaptation” or decreased energy expenditure that occurs with surgery-induced weight loss and…”
BackgroundLow Carbohydrate Diets for Diabetic Cardiomyopathy: A Hypothesis
Kleissl-Muir, S., Rasmussen, B., Owen, A. J., Zinn, C., & Driscoll, A. L. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.865489 · Cited by 192
Muscle Insulin Resistance Elicits Muscle Atrophy in Obesity
Razi, O., Zamani, N., Saeidi, A., Hadjicharalambous, M., Ayed, K., Hackney, A. C., Coso, J. D., Laher, I., Muscogiuri, G., & Zouhal, H. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00672-6 · Cited by 13
Endocrinological aspects of sarcopenic obesity
Minnetti, M., Poggiogalle, E., Frigerio, F., Piciocchi, C., Pierantozzi, G., Vincenzo, O. D., Pinto, A., Gianfrilli, D., Isidori, A. M., Migliaccio, S., et al. (2026) · Annals of Medicine · doi:10.1080/07853890.2026.2626085 · Cited by 14
“In turn, decreased muscle mass worsens systemic insulin resistance, establishing a vicious cycle that amplifies both sarcopenia and metabolic disease [128,129].”
Sarcopenic Obesity: A Comprehensive Approach for Postmenopausal Women
Park, J. Y., Chung, Y., Song, J., Kil, K., Lee, H. Y., Chae, J., & Kim, J.-H. (2024) · Journal of Menopausal Medicine · doi:10.6118/jmm.24004 · Cited by 12
Yu, X., Chao, J., Wang, X., Dun, S., Song, H., Guo, Y., Zhang, H., Yao, Y., Liu, Z., Wang, J., et al. (2025) · Clinical Nutrition · doi:10.1016/j.clnu.2025.03.001 · Cited by 12
He, H., Pan, L., Wang, D., Liu, F., Du, J., Pa, L., Wang, X., Cui, Z., Ren, X., Wang, H., et al. (2023) · Experimental Gerontology · doi:10.1016/j.exger.2023.112155 · Cited by 11
“Myokines released from skeletal muscle have key role in maintaining human organs health and take part in the progression of cardiometabolic diseases (Hong and Choi, 2020; Sakuma et al., 2015).”
BackgroundAbe, T., Yoshimura, Y., Sato, Y., Nagano, F., & Matsumoto, A. (2023) · Journal of Nutritional Science and Vitaminology · doi:10.3177/jnsv.69.454 · Cited by 12
Associations Between Life's Essential 8 and Insulin Resistance Among Nondiabetic Adults
Pang, S., Wang, Y., Sun, S., Wang, S., Li, F., Zhao, W., & Wu, X. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.033997 · Cited by 11
“3,4 Notably, insulin resistance (IR) stands out as a significant causal factor.”
(2026) · doi:10.1007/s13668-026-00777-x · Cited by 10
“…declines in skeletal muscle mass index (SMI) and function often occur in parallel with increases in total FM, while the clinical course of obesity is characterized by a range of risk factors for sar-copenia, including elevated oxidative stress, inflammation, and the burden of NCDs [15 , 16 ].”
Lázaro-Martínez, S., Orueta-Jiménez, T. D. J., Vázquez, P. I. A., Castillo-Ávila, R. G., Tovilla‐Zárate, C. A., Hernández-Gil, K. D. C., Quezada-González, R., Magaña, P. L., López‐Narváez, M. L., & García-González, L. E. (2022) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2022.10.002 · Cited by 15
Mitochondrial disorders as a mechanism for the development of obese Sarcopenia
Liao, T., Xiong, L., Wang, X., Yang, S., & Liang, Z. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01192-w · Cited by 10
“Dysfunctional mitochondria are associated with many metabolic disorders, and mitochondria are metabolic organelles that act centrally in lipid and protein synthesis and are related to obese sarcopenia [34, 35].”
BackgroundImmunogenetic Aspects of Sarcopenic Obesity
Mazurkiewicz, Ł., Czernikiewicz, K., & Grygiel‐Górniak, B. (2024) · Genes · doi:10.3390/genes15020206 · Cited by 14
“…muscle-produced IL-6 positively impacts muscle regeneration and hypertrophy; however, in persistent inflammatory conditions, like the obese state, it acts as a pro-inflammatory, activating the MAP3K8 expression, further influencing NF-kB and JNK transcription factors, leading to IR [10,55,56].”
BackgroundSarcopenic obesity and brain health: A critical appraisal of the current evidence
Booranasuksakul, U., Guan, Z., Macdonald, I. A., Tsintzas, K., Stephan, B. C. M., & Siervo, M. (2025) · Nutrition Bulletin · doi:10.1111/nbu.12725 · Cited by 10
Sarcopenia and sarcopenic obesity in cardiovascular disease: a comprehensive review
Tan, L. F., Sia, C., & Merchant, R. A. (2025) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2024-233 · Cited by 10
Age‐Stratified Associations of Sarcopenic Obesity With Mortality in Type 2 Diabetes
Yamamoto, S., Hashimoto, Y., Takahashi, F., Murai, M., Yoshioka, N., Saijo, Y., Munekawa, C., Nakajima, H., Kitagawa, N., Osaka, T., et al. (2026) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.70211 · Cited by 13
Xu, Y., Hu, T., Shen, Y., Wang, Y., Ma, X., & Bao, Y. (2022) · The journal of nutrition health & aging · doi:10.1007/s12603-022-1871-z · Cited by 11
Cao, X., Yang, B., & Zhou, J. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1166341 · Cited by 10
“…Longevity Survey (CLHLS) database, since those included elderly population aged 65 years and older are reported to be susceptible to SO, as well as exhibiting an elevated level of cognitive impairment (Ida et al., 2018; Hong, 2020), with a diverse range of observed variables (Ji et al., 2022).”
BackgroundSong, J., Zhou, D., Li, J., Wang, M., Jia, L., Lan, D., Song, H., Ji, X., & Meng, R. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14759 · Cited by 11
“33 Skeletal muscles, the primary organs for glucose disposal, play essential roles in maintaining glucose homeostasis via insulin-mediated signaling pathways.”
BackgroundMontazeri‐Najafabady, N., Dabbaghmanesh, M. H., Nasimi, N., Sohrabi, Z., & Chatrabnous, N. (2021) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-021-04314-5 · Cited by 12
Kim, N. Y., & Choi, Y. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12113676 · Cited by 14
Gastrointestinal hemorrhage complicating systemic neurofibromatosis.
Melin, M. M., Grotz, R. L., & Nivatvongs, S. (1994) · PubMed · Cited by 11
Chen, W., Yuan, Q., Li, X., Yao, J., Yuan, L., Chen, X., & Gao, B. (2024) · Cancer Medicine · doi:10.1002/cam4.7452 · Cited by 9
“28 Sarcopenia and visceral fat obesity are both clinically detectable and diagnosable.”
BackgroundGuan, Z., Stephan, B. C. M., Donini, L. M., Prado, C. M. M., Sim, M., & Siervo, M. (2024) · Proceedings of The Nutrition Society · doi:10.1017/s0029665124007559 · Cited by 14
“During the pathophysiological development of SO, hyperinsulinemia, induced by insulin resistance, may trigger the renin-angiotensin-aldosterone system (58) .”
InfluentialCano-Martínez, A., Méndez-Castro, J. A., García-Vázquez, V. E., Carreón‐Torres, E., Díaz‐Díaz, E., Sánchez-Aguilar, M., Castrejón-Téllez, V., & Rubio-Ruiz, M. E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104952 · Cited by 10
“This communication may lead to a negative feedback loop, which aggravates SO and insulin resistance (IR) [5].”
Tang, W., Yu, J., Yang, K., Jia, J., Mao, X., & Song, F. (2025) · BMC Public Health · doi:10.1186/s12889-025-24090-4 · Cited by 11
“Age-related lifestyle changes, such as physical inactivity and nutritional decline, contribute to alterations in body composition, notably reductions in skeletal muscle mass and function [3, 4].”
Gandham, A., Prokopidis, K., Glavas, C., Scott, D., & Lorentzon, M. (2026) · Osteoporosis International · doi:10.1007/s00198-025-07801-w · Cited by 10
“Moreover, the accumulation of lipid-derived metabolites, including ceramides and acylcarnitines, are commonly observed in obesity and sarcopenic obesity [112].”
Unraveling the metabolic pathways between atherosclerosis and sarcopenia
Yu, M., Ge, L., Fu, C., & Zhao, R. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1762825 · Cited by 13
“This creates a state of relative muscle ischemia, which exacerbates metabolic stress, limits exercise capacity, and contributes to further muscle wasting, thereby directly feeding into the sarcopenic process (5, 57, 63) (As shown in Figure 2).”
Togashi, S., Wakabayashi, H., Ohinata, H., Nishioka, S., Kokura, Y., & Momosaki, R. (2022) · Nutrients · doi:10.3390/nu14214494 · Cited by 14
“Obesity can independently lead to loss of muscle mass and function, due to the negative impact of adipose tissue-dependent metabolic derangements, such as oxidative stress, inflammation, and insulin resistance, all of which negatively affect muscle mass [34].”
BackgroundMiedany, Y. M. E., Mahran, S., & Elwakil, W. (2023) · Egyptian Rheumatology and Rehabilitation · doi:10.1186/s43166-023-00199-5 · Cited by 9
“On the other hand, obesity can cause independent muscle mass and function loss due to the negative impact of adipose tissue-dependent metabolic derangements such as oxidative stress, inflammation, and insulin resistance, all of which have a negative impact on muscle mass [40].”
BackgroundYu, E. H., Lee, H. J., Kim, H. J., Kim, I. H., Joo, J. K., & Na, Y. J. (2023) · Journal of Menopausal Medicine · doi:10.6118/jmm.23014 · Cited by 11
“A Korean study demonstrated a pathophysiological relationship between insulin resistance and cardiometabolic diseases in patients with sarcopenic obesity [10].”
BackgroundGong, Y., Yang, Y., Zhang, X., & Li, T. (2025) · Systematic Reviews · doi:10.1186/s13643-025-02825-z · Cited by 10
“The mechanisms underlying the preventive and therapeutic effects of exercise on SO may include enhancing insulin sensitivity [20], reducing inflammatory responses, restoring normal mitochondrial function, and reducing muscle fat infiltration [21], among others [15].”
Lee, J., Cho, A., & Kwon, Y. (2021) · Clinical Nutrition · doi:10.1016/j.clnu.2021.12.015 · Cited by 9
Sakai, M., Sohda, M., Uchida, S., Yamaguchi, A., Watanabe, T., Saito, H., Ubukata, Y., Nakazawa, N., Kuriyama, K., Sano, A., et al. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-11497-1 · Cited by 9
“Fat accumulation in muscle tissue promotes a proinflammatory cascade and oxidative stress, resulting in mitochondrial dysfunction, damaged insulin signaling, and muscle atrophy.(19) The atrophy of skeletal muscle cells reduces the expression of GLUT4 in muscle fibers and inhibits insulin-mediated glucose uptake throug…”
BackgroundLi, N., Chen, S., He, Y., Chen, Y., Duan, X., He, W., Wang, Q., Liu, S., Liu, T., & Fang, H. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1522287 · Cited by 8
Bufano, A., Cartocci, A., Benenati, N., Ciuoli, C., Batzibal, M. S., Bombardieri, A., Sareri, G. I., Sannino, I., Tirone, A., Voglino, C., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1369584 · Cited by 8
“Independently of age, obesity can lead to loss of muscle mass and function due to the negative impacts of adipose tissue-dependent metabolic disorders, such as oxidative stress, in fl ammation, and insulin resistance, all of which negatively affect muscle mass (6).”
BackgroundKoh, Y., Hsu, H., Ho, P.-Y., Lin, W., Hsu, K.-Y., Majeed, A., Ho, C., & Pan, M. (2025) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c07798 · Cited by 9
Are strategies to increase muscle mass and strength as effective in people with type 2 diabetes?
Al-Awadi, A. A., Gray, S. R., & Al‐Ozairi, E. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09947-8 · Cited by 12
“In addition, insulin resistance in people with T2D can accelerate muscle loss and weakness by disrupting insulin’s anabolic signalling pathways, reducing glucose transporter type 4 (GLUT4) translocation, and impairing mitochondrial function [33, 39].”
Xiao, W., Xu, T., Liao, Y., Xu, Y., Fan, Z., Li, C., & Zhang, X. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1511232 · Cited by 8
“The relationship between sarcopenia and IR is affected by obesity, particularly in the context of sarcopenic obesity, where IR status is negatively correlated with skeletal muscle mass (40).”
The impact of sarcopenic obesity on cancer clinical outcomes
Köylü, B., Sulu, C., Yumuk, V., & Yumuk, P. F. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.07.002 · Cited by 8
Liu, H., Li, S., Zhang, X., Long, W., Liao, H., Lu, L., Ni, S.-H., & Yang, Z. (2025) · JMIR Aging · doi:10.2196/80115 · Cited by 8
“IR may disrupt muscle protein balance, leading to decreased muscle mass and functionality, while sarcopenia can impair glucose metabolism [24].”
Masri, D. E., Itani, L., Tannir, H., Kreidieh, D., & Ghoch, M. E. (2021) · Clinics and Practice · doi:10.3390/clinpract11030069 · Cited by 8
Old muscle, new tricks: a clinician perspective on sarcopenia and where to next
Schütze, K., Schopp, M., Fairchild, T. J., & Needham, M. (2023) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001185 · Cited by 10
Xiao, H., Hu, L., Xie, M., Du, Y., & Liao, D. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1382254 · Cited by 9
Duan, C., Wu, M., Xia, W., Zhuang, L.-P., & Sun, J. (2024) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyae080 · Cited by 8
Lou, Y., Xie, Y., Jiang, Q., Huang, S., Wang, X., Wang, L., Wang, H., & Cao, S. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16016 · Cited by 9
“10 – 14 Previous findings have examined the effect of SO on diabetes based on a static perspective.”
dos Santos, M. P., Barbosa, M. V., Souza, N. C., & Martucci, R. B. (2025) · Nutrition Research · doi:10.1016/j.nutres.2025.04.001 · Cited by 8
Luo, Y., Chen, X., Liu, Y., Xu, Y. J., Liu, G., & Han, B. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1581146 · Cited by 7
“However, Donini et al. (31) found a weaker association between SO and carotid atherosclerosis, suggesting that population heterogeneity (e.g., race and age), differences in SO diagnostic criteria (muscle strength and mass assessment methods), and atherosclerosis detection methods (e.g., ultrasound…”
Shin, H. E., Jang, J. Y., Arai, H., Lim, W. S., Chen, L., Kim, M., & Won, C. W. (2025) · Experimental Gerontology · doi:10.1016/j.exger.2025.112936 · Cited by 9
Seliem, M. A., & Ragab, M. A. (2026) · Nutrition & Metabolism · doi:10.1186/s12986-026-01123-2 · Cited by 8
“Rather than simply suppressing inflammation, the aberrant SOCS3 activity causes the degradation of IRS-1/2 that is basically usurping the negative feedback loop and imposing insulin resistance and a catabolic state [8].”
InfluentialLu, Y., Tian, J., Wu, L., Xia, Q., & Zhu, Q. (2023) · BMC Geriatrics · doi:10.1186/s12877-023-04076-w · Cited by 7
Zhu, Q., Zhang, T., Cheang, I., Lu, X., Shi, M., Zhu, X., Liao, S., Gao, R., Li, X., & Yao, W. (2023) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-023-06700-7 · Cited by 7
“Impaired muscle mass may also be associated with a complex interplay of factors such as oxidative stress, mitochondrial dysfunction, circulating pro-inflammatory cytokines, inflammatory macrophage infiltration of muscle tissue, and hormonal changes [35, 36].”
BackgroundWang, W., Gu, X., Cao, Z., Wang, X., Lei, Y., Xu, X., Wang, S., Wu, T., & Bao, Z. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01879-z · Cited by 7
“IL-6, working as a pro-inflammatory factor, can selectively stimulate protein degradation and promote fat synthesis in human skeletal muscle [22].”
BackgroundAljawini, N., & Habib, S. S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12206642 · Cited by 7
“These factors negatively impact muscle health [48], leading to the possibility that obesity could contribute to the independent decline of muscle mass and strength [49].”
BackgroundZhuang, M., Shi, J., Liu, J., He, X., & Chen, N. (2023) · BMC Geriatrics · doi:10.1186/s12877-023-04592-9 · Cited by 7
“Several studies reported that SO may result in a two-to threefold higher risk of functional disability [3] as well as hypertension [4], hyperglycaemia [4], dys-lipidaemia [5], type 2 diabetes [6] and insulin resistance (IR) [5] compared with sarcopenia alone or obesity alone.”
BackgroundApproaching the Sarcopenic Patient with Nonalcoholic Steatohepatitis-related Cirrhosis
Gallo, P., Flagiello, V., Falcomatà, A., Pasquale, G. D., D’Avanzo, G., Terracciani, F., Picardi, A., & Gentilucci, U. V. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2023.00207 · Cited by 12
Das, G., Setlur, K., Jana, M., Ramakrishnan, L., Jain, V. S., Meena, J. P., Gupta, A. K., Dwivedi, S. N., & Seth, R. K. (2024) · Supportive Care in Cancer · doi:10.1007/s00520-024-09025-w · Cited by 11
“Compounded with the effects of treatment, sarcopenic obesity in childhood cancer survivors ultimately predisposes to an increased risk of metabolic and cardiovascular late effects [5] resulting in poor quality of life [9].”
Tannir, H., Itani, L., Kreidieh, D., Masri, D. E., & Ghoch, M. E. (2022) · Clinics and Practice · doi:10.3390/clinpract12010014 · Cited by 7
Association between Body Composition Contents and Hepatic Fibrosis in Sarcopenic Obesity
Kim, T., Jeong, C., Lee, C., Noh, S.-H., Lim, D. W., Kim, J. W., Kim, H. J., & Kim, Y. R. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134279 · Cited by 7
The consumption of micronutrients in relation to calorie intake and risk of insulin resistance
Piyathilake, C. J., Badiga, S., Hernandez, A., Brill, I. K., & Jolly, P. E. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.02.007 · Cited by 188
Effects of Weight Loss on Insulin Resistance and Liver Health in T2DM and NAFLD Patients
Xu, Y., Meng, Q., & Wu, P. (2025) · Medical Science Monitor · doi:10.12659/msm.947157 · Cited by 8
“Given insulin’s dual anti-inflammatory and pro-inflammatory properties, IR and inflammation form a vicious cycle, accelerating the development of MASLD and other metabolic disorders [19].”
Liu, J., Ji, F., & Kim, J.-H. (2025) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2025.103151 · Cited by 8
“Furthermore, the imbalance in body composition induced by sarcopenic obesity in-tensifies systemic inflammation, insulin resistance, and lipid metabolism dysfunction (S.-h. Hong and Choi, 2020), all of which are key pathways in the pathogenesis of CVD.”
Role of immunity and inflammation in sarcopenic obesity
Ma, Y. F., Li, X., Lin, X., Zhang, K., & Leng, J. (2025) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2025.110077 · Cited by 8
Shang‐Guan, Z., Lin, G., Liu, Z.-Y., Zhong, Q., Huang, Q., Li, P., Xie, J., Wang, J.-B., Lü, J., Chen, Q., et al. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07146-z · Cited by 7
“Leptin resistance due to chronically high leptin levels leads to a poor weight loss response [49, 50] because it interferes with leptin binding to the satiety center in the ventral medial nucleus of the hypothalamus, disrupting the inhibitory effect of leptin on the food-promoting hormone…”
The obesity-related mutation gene on nonalcoholic fatty liver disease
Chen, Y., Chen, C., Huang, J., Su, W.-H., Li, C., Chen, W.-S., Lin, E.-S., Chuang, W., Yu, M., & Wang, S. (2024) · Human Genetics · doi:10.1007/s00439-024-02686-x · Cited by 7
“IR and inflammation are a continuous cycle that promotes each other and accelerates the development of metabolic disorders and NAFLD while involving lipotoxicity (Hong and Choi 2020).”
Abad-González, Á. L., Martín, S. V., Argente, M., Civera, M., García-Malpartida, K., Juan, C. S., Artero, A., Palmas-Candia, F. X., Perelló-Camacho, E., Salom, C., et al. (2025) · Nutrients · doi:10.3390/nu17030499 · Cited by 8
“Simultaneously, IR upregulates protein degradation through the ubiquitin–proteasome system, resulting in reduced muscle mass. Additionally, defects in GLUT-4 expression and function further impair glucose uptake in muscle and adipose tissues, leading to significant metabolic disturbances [11].”
Jiang, D., Liu, C., Chen, Y., Xing, X., & Zheng, D. (2021) · Endocrine Journal · doi:10.1507/endocrj.ej21-0343 · Cited by 6
“Aging can cause changes in body composi‐ tion, resulting in fat accumulation and an increased fat content in muscle, resulting in the decline of muscle quality and the damage of corresponding organ function [1, 2].”
BackgroundGómez‐Barroso, M., Vargas-Vargas, M. A., Peña‐Montes, D. J., Cortés‐Rojo, C., Saavedra‐Molina, A., Sánchez‐Duarte, E., Rodríguez-Orozco, A. R., & Montoya-Pérez, R. D. C. (2022) · Biology · doi:10.3390/biology11091367 · Cited by 7
“These altered parameters are indicators of alterations in muscle cell metabolism, which is eventually associated with obesity, deterioration of muscle strength, and resistance to fatigue [31].”
BackgroundInter-organ Crosstalk and the Effect on the Aging Process in Obesity
Armutçu, F., & Özen, O. A. (2023) · Current Aging Science · doi:10.2174/1874609816666230223110458 · Cited by 6
Hu, F., Zhang, G., Xu, Z., Zuo, Z., Huang, N., Ge, M., Liu, X., & Dong, B. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1356878 · Cited by 10
“Insulin resistance serves as the central mechanism underlying the development of SO (42).”
BackgroundDecoding the mechanistic basis of liver–muscle communication in health and disease
Gamil, N. M., Elsayed, H. A., Salah, E. T., Mostafa, H. A., El‐Shiekh, R. A., Ghaiad, H. R., & Eitah, H. E. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05015-3 · Cited by 6
“Inflammatory cytokines released by adipose tissue macrophages are thought to accelerate skeletal muscle breakdown (Hong and Choi 2020).”
Metadata
- Authors
- Hong, S.-H., & Choi, K. M.
- Affiliations
- Korea University (KR)
- Corresponding author
- Choi, Kyung Mook
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-01-13
- Volume
- 21
- Issue
- 2
- Pages
- 494
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7013734
- OpenAlex
- W2999215393
- Cited by
- 390
- References
- 153
- Citations by year
- 2026: 91 · 2025: 87 · 2024: 68 · 2023: 72 · 2022: 40 · 2021: 20 · 2020: 11
- FWCI
- 4.59
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Korea Christian University (Q1625561)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Keywords
- sarcopenic obesity, insulin resistance, cardiometabolic disease, type 2 diabetes, non-alcoholic fatty liver disease, cardiovascular disease, muscle atrophy, mitochondrial dysfunction, oxidative stress, myokines, adipokines, insulin signaling, aging
- MeSH terms
- Animals, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Insulin Resistance, Mitochondria, Liver, Mitochondria, Muscle, Obesity, Sarcopenia, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.